AIM:The aim of this study was to determine the correlation of changes in left ventricular mass, with changes in office blood pressure (BP) and in 24-h ambulatory (ABP), with the trough-to-peak (T/P) ratio and with the smoothness index (SI), as induced by antihypertensive treatment with lercanidipine.
METHODS:This was done through an observational, prospective, open, non-comparative, single centre, pilot study in patients naïve to antihypertensive therapy. All patients were treated with lercanidipine 10-20 mg/day plus hydrochlorothiazide 12.5-25 mg/day if treated BP exceeded an arbitrarily defined safety level (>160/100 mmHg) after 1 month on monotherapy. ABP monitoring was repeated after 1 month and after 6 months. Two-dimensional mode echocardiography was performed twice, at the beginning and end of the study. Seventeen patients were included in the final analysis (aged 45.8 +/- 10.7 years, 35% women).
RESULTS:Treatment-induced changes in left ventricular mass index (LVMI) were not found to correlate neither with changes in office BP, with changes in ABP values, nor with T/P. However, a significant correlation was found between LVMI changes and SI at 6 months (r=0.50, P=0.039).
CONCLUSION:The results of this study suggest that the SI has a higher predictive value, compared to other BP-derived parameters, for treatment-induced LVMI changes, in hypertensive patients treated with lercanidipine.
-
【Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial.].
【高血压患者乐卡地平所致平滑度指数和谷峰比与左心室质量指数变化的相关性。试运行。】
复制标题
收藏
DOI：文章类型：杂志文章
复制DOI
译文
目的：本研究的目的是确定左心室质量变化与办公室血压（BP）和24小时非卧床（ABP）变化与波峰（T / P）的相关性乐卡地平抗高血压治疗所致的比例和平滑度指数（SI）。
方法：这是通过一项观察性，前瞻性，开放性，非对照性，单中心，前瞻性研究对未接受降压治疗的患者进行的。如果在单药治疗1个月后，经治疗的BP超过任意定义的安全水平（> 160/100 mmHg），则所有患者均接受10-20 mg /天的乐卡地平加12.5-25 mg /天的氢氯噻嗪治疗。 1个月后和6个月后重复进行ABP监测。在研究开始和结束时，二维模式超声心动图检查进行了两次。最终分析包括17名患者（年龄45.8 / 10.7岁，女性35％）。
结果：未发现治疗引起的左心室质量指数（LVMI）的变化与办公室血压的变化，ABP值的变化或T / P均无关。然而，发现6个月时LVMI的变化与SI之间存在显着相关性（r = 0.50，P = 0.039）。
结论：本研究结果表明，与其他BP衍生参数相比，SI对接受lercanidipine治疗的高血压患者因治疗引起的LVMI变化具有更高的预测价值。
方法：这是通过一项观察性，前瞻性，开放性，非对照性，单中心，前瞻性研究对未接受降压治疗的患者进行的。如果在单药治疗1个月后，经治疗的BP超过任意定义的安全水平（> 160/100 mmHg），则所有患者均接受10-20 mg /天的乐卡地平加12.5-25 mg /天的氢氯噻嗪治疗。 1个月后和6个月后重复进行ABP监测。在研究开始和结束时，二维模式超声心动图检查进行了两次。最终分析包括17名患者（年龄45.8 / 10.7岁，女性35％）。
结果：未发现治疗引起的左心室质量指数（LVMI）的变化与办公室血压的变化，ABP值的变化或T / P均无关。然而，发现6个月时LVMI的变化与SI之间存在显着相关性（r = 0.50，P = 0.039）。
结论：本研究结果表明，与其他BP衍生参数相比，SI对接受lercanidipine治疗的高血压患者因治疗引起的LVMI变化具有更高的预测价值。
